Therapeutic monoclonal antibodies at phase 3 clinical study for management of Covid-19

	Therapeutic monoclonal antibodies at phase 3 clinical study for management of Covid-19
Pathobiology Reserach
Article 4, Volume 23, Issue 0, 2021, Pages 51-56 PDF (1.12 M)
Document Type: Analytic Review
Authors
Mohsen Rezaei^* ¹; somayeh Handali²
¹Department of Toxicology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
²Medical Biomaterial Research Center (MBRC), Tehran University of Medical Sciences, Tehran, Iran
Abstract
The new coronavirus was firstly identified in the late December 2019 that causes severe respiratory and other organ complications in Covid-19 patients. Although many attempts have been employed to introduce and provide effective medications against this infection, there is still no definitive treatment for the infection. However some agents have shown promising effects in patients and some others are in preliminary or clinical studies. Monoclonal antibodies are of great interest in the treatment of Covid-19, but despite the fact that more than 120 clinical trials have been performed or are being completed; only tocilizumab has shown promising results and is sometimes used in therapeutic protocols. In this review, therapeutic monoclonal antibodies against Covid-19 that are currently in phase 3 or higher clinical trial have been discussed.
Keywords
Covid-19; monoclonal antibody; Phase 3 clinical study
References

Statistics Article View: 141 PDF Download: 61